Heart protection from GLP-1 drugs fades quickly after stopping, study finds

A Washington University study of more than 333,000 U.S. veterans with type 2 diabetes found that continuous GLP-1 therapy reduced cardiovascular risk by about 18% after three years; stopping the medication for six months raised risk by 4%, after one year by 14%, and after two years by 22%, with restarting yielding only partial protection, highlighting the importance of long‑term use and accompanying lifestyle changes.